FC26: The Next Chapter in Psoriasis Therapy: The Role of New and Emerging TYK2 Inhibitors

Releases on
November 23, 2026
Starts at
9:00am EST
Earn up to
0.75 AMA PRA Category 1 Credit(s)™
In this 45-minute symposium, live from Fall Clinical 2026, Linda Stein Gold, MD, Ron Vender, MD, and Edward (Ted) Lain, MD, MBA, discuss the evolving role of TYK2 inhibitors in psoriasis management. Faculty will explore updated treatment targets, review the latest efficacy and safety data for TYK2 inhibitors, and share practical insights on incorporating these therapies into individualized treatment strategies for patients with psoriasis.
FC26: The Next Chapter in Psoriasis Therapy: The Role of New and Emerging TYK2 Inhibitors
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.